Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to ClinicMELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” ...

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for ...

Multiplex assay tech detects multi-biomolecules in single samples on xMAP/CBA, with high sensitivity and consistency ...

(RTTNews) - Akoya Biosciences, Inc. (AKYA), Thursday announced the launch of a new multiplex immunofluorescence or mIF assay to advance antibody-drug conjugate or ADC development in breast cancer, ...

The Stagljar Lab is a global leader in proteomics and chemical genomics, specializing in unraveling protein-protein interactions of human membrane proteins. Pivotal in cancer and rare genetic diseases ...

Assays to measure homologous recombination deficiency (HRD) in ovarian cancer vary widely, underscoring the need for standardization, since inconsistent assay results can influence treatment decisions ...

The shift towards utilizing complex organ-like structures developed from stem cells or tissue samples is becoming essential; these organoid models are leading the way to next-generation, animal-free ...

Please provide your email address to receive an email when new articles are posted on . The CNSide assay aims to help clinicians with early diagnosis, treatment plans for those with CNS cancers. The ...